C4 Therapeutics, Inc.
Here’s whether C4 Therapeutics, Inc. (CCCC) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Neutral.
Positives: trading above the 200-day MA (long-term uptrend intact); 50-day MA is rising (+3.99% over 10 days); strong 1-year return of +48.5%; 3-month momentum positive (+18.1%). Concerns: below the 50-day MA (medium-term momentum negative); declining volume on rally — weak conviction (0.80x 30d avg). Currently 34.2% off its 52-week high. Score: +3/7.
CCCC is holding above its long-term 200-day MA ($2.83) but has slipped below the 50-day MA ($3.90), pointing to short-term weakness in an otherwise intact trend. An RSI of 32.2 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +48.5% compares to +16.5% for SPY (beat the market by 32.0%). The current 34.2% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.